)

Kestra Medical Technologies (KMTS) investor relations material
Kestra Medical Technologies Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Achieved Q1 FY26 revenue of $19.4 million, up 52% year-over-year, driven by higher market share, new account activations, and improved collection efforts from an expanded revenue cycle management team.
Prescription volume for the Assure system reached 4,205, up 51% year-over-year, reflecting expanded reach to patients at risk of cardiac arrest.
Focused on expanding sales and commercial operations, improving revenue cycle management, scaling device fleet, and building clinical evidence for the Assure system.
Achieved a major clinical milestone by concluding enrollment in the FDA post-approval study, with results to be presented at a major cardiology conference.
Net loss attributable to common shareholders was $25.8 million, a 16% increase from the prior year, primarily due to higher operating expenses as the company scaled commercial operations and transitioned to a public company.
Financial highlights
Revenue grew 52% year-over-year to $19.4 million in Q1, driven by increased prescriptions and market share gains.
Gross profit was $8.9 million, up 111% year-over-year, with gross margin expanding to 45.7% from 32.9% in the prior year period.
GAAP operating expenses were $37.7 million, including $2.9 million in non-recurring public company costs; adjusted operating expenses were $30.3 million.
GAAP net loss was $25.8 million, and adjusted EBITDA loss was $19.4 million, both higher than the prior year due to growth investments.
Cash and cash equivalents totaled $201.5 million as of July 31, 2025, following the IPO in March 2025, which raised $215.8 million in net proceeds.
Outlook and guidance
Fiscal 2026 revenue guidance raised to $88 million, a 47% increase over fiscal 2025 and up from prior guidance of $85 million.
Expect continued gross margin expansion, targeting 70%+ margins over the next few years.
Revenue per fit expected to benefit from higher in-network patient mix and improved revenue cycle management.
Management expects continued revenue growth as patient adoption increases and operational efficiencies are realized.
Steady, not back-end loaded, revenue growth anticipated throughout the year as commercial team expands.
Next Kestra Medical Technologies earnings date

Next Kestra Medical Technologies earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage